Feels "very good" about product pipeline. Says remains "vigilant" regarding M&A, but will not due anything "out of desperation."
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on JNJ:
- Johnson & Johnson Earnings Report: Is it a Beat?
- JNJ Up as Q1 Results Beat Estimates, Raises Outlook
- Johnson & Johnson raises quarterly dividend 5.3% to $1.19 from $1.13 per share
- Genmab announces Q1 net sales of DARZALEX $2.26B
- Johnson & Johnson raises FY23 adjusted EPS to $10.60-$10.70 from $10.45-$10.65